Schroder Investment Management Group’s Amicus Therapeutics FOLD Stock Holding History

Schroder Investment Management Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,018,190	Closed	-$5.83M	–	1208
2025 Q2	$5.83M	Buy	1,018,190 +649,177	+176%	+$4.19M	﹤0.01%	739
2025 Q1	$3.11M	Hold	369,013	–	–	﹤0.01%	847
2024 Q4	$3.47M	Hold	369,013	–	–	﹤0.01%	840
2024 Q3	$3.95M	Sell	369,013 -140,987	-28%	-$1.54M	﹤0.01%	828
2024 Q2	$5.06M	Hold	510,000	–	–	0.01%	779
2024 Q1	$6.01M	Hold	510,000	–	–	0.01%	748
2023 Q4	$7.24M	Buy	+510,000	New	+$5.79M	0.01%	695

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Schroder Investment Management Group's FOLD Position: Q3 2025 in Review

Schroder Investment Management Group sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 1,018,190 shares — an estimated $5.83M sold.

Schroder Investment Management Group first reported a position in FOLD in Q4 2023 and held it in 7 quarters. The position peaked at $7.24M in Q4 2023. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

Schroder Investment Management Group reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
Schroder Investment Management Group sold 1,018,190 Amicus Therapeutics shares in Q3 2025, an estimated $5.83M.
Schroder Investment Management Group first reported a position in Amicus Therapeutics in Q4 2023 and held it in 7 quarters.
Schroder Investment Management Group's Amicus Therapeutics position peaked at $7.24M in Q4 2023.
287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Schroder Investment Management Group's 13F filing for Q3 2025, filed 13 Nov 2025.